Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone

NCT ID: NCT00223145

Last Updated: 2025-01-27

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 600 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2000-12-31
• Study Completion Date: 2027-12-31

Brief Summary

The hypothesis of the proposed study would be that, due to the six months of total androgen blockade, which would include neoadjuvant hormonal therapy for four months and concomitant hormonal therapy for two months with irradiation, the investigators could reduce local failure rates for these two dosage levels, namely 70 Gy and 76 Gy. Since increasing the dose to the prostate also seems to reduce local relapse rates, the results of the two hormonal therapy groups would be compared with the results of prostate irradiation at doses of 76 Gy. This study would verify the possibility of compensating a six Gy dosage increase of radiation therapy with six months of hormonal therapy between the 70 Gy and 76 Gy groups who received hormonal therapy, and also match these results with a dose escalation to the prostate of 76 Gy. In the future, this could result in more therapeutic choices, such as reducing the doses of radiation therapy and, consequently, its related complications, if hormonal therapy proves to be beneficial; or rather, to continue in the direction of dose escalation for this intermediate-risk patient group, everything being correlated to the side effects of hormonal therapy and irradiation.

Conditions

Prostate Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm 1

Androgen blockade for 6 months + Radiotherapy 70 Gy

Group Type: EXPERIMENTAL

Radiotherapy 70 Gy

Intervention Type: RADIATION

Radiotherapy to the prostate

Androgen blockade

Intervention Type: DRUG

Duration : 6 months

Arm 2

Androgen blockade for 6 months + Radiotherapy 76 Gy

Group Type: EXPERIMENTAL

Radiotherapy 76 Gy

Intervention Type: RADIATION

Radiotherapy to the prostate

Androgen blockade

Intervention Type: DRUG

Duration : 6 months

Arm 3

Radiotherapy alone with 76 Gy

Group Type: ACTIVE_COMPARATOR

Radiotherapy 76 Gy

Intervention Type: RADIATION

Radiotherapy to the prostate

Interventions

Radiotherapy 70 Gy

Radiotherapy to the prostate

Intervention Type: RADIATION

Radiotherapy 76 Gy

Radiotherapy to the prostate

Intervention Type: RADIATION

Androgen blockade

Duration : 6 months

Intervention Type: DRUG

Other Intervention Names

Bicalutamide 50 mg; Goserelin 10.8 mg

Eligibility Criteria

Inclusion Criteria

• Patients with stage T1 or T2 untreated adenocarcinoma of the prostate, with a Gleason score that is less than or equal to 6, as well as a prostate-specific antigen (PSA) between 10-20 (intermediate risk) or patients with stage T1 or T2 untreated adenocarcinoma of the prostate, with a Gleason score that is equal to 7, as well as a PSA equal to or less than 20 (intermediate risk).
• Performance status score of 0-1
• Patients must sign a consent form before starting the study.
• No evidence of regional disease
• Patients with a previous history of cancer are eligible on the condition that they have been disease-free for more than five years.
• Non-invasive epidermoid cancers of the skin are eligible.
• The patient must be available for treatments and follow-up visits.
• No evidence of metastatic disease, confirmed by a negative bone scan.

Exclusion Criteria

• Severe medical or psychiatric problems that may compromise study compliance
• Chronic hepatic disease; abnormal hepatic function, i.e. aspartate aminotransferase and alanine aminotransferase > 1.5 times the upper normal limit.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: collaborator

Abdenour Nabid

OTHER

Sponsor Role: lead

Responsible Party

Abdenour Nabid

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Abdenour Nabid, MD

Role: PRINCIPAL_INVESTIGATOR

CRC - CHUS

Locations

Centre de Recherche Clinique du CHUS

Sherbrooke, Quebec, Canada

Countries

Canada

References

Nabid A, Carrier N, Vigneault E, Van Nguyen T, Vavassis P, Brassard MA, Bahoric B, Archambault R, Vincent F, Bettahar R, Wilke D, Souhami L. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial. Eur J Cancer. 2021 Jan;143:64-74. doi: 10.1016/j.ejca.2020.10.023. Epub 2020 Dec 3.

Reference Type: DERIVED

PMID: 33279855 (View on PubMed)

Other Identifiers

DC-990-0049

Identifier Type: -

Identifier Source: secondary_id

DC-990-0049,1

Identifier Type: -

Identifier Source: org_study_id